Zhou, Z and Ofori-Asenso, R and Curtis, AJ and Breslin, M and Wolfe, R and McNeil, JJ and Murray, AM and Ernst, ME and Reid, CM and Lockery, JE and Woods, RL and Tonkin, AM and Nelson, MR, Association of statin use with disability-free survival and cardiovascular disease among healthy older adults, Journal of the American College of Cardiology, 76, (1) pp. 17-27. ISSN 0735-1097 (2020) [Refereed Article]
© 2020 by the American College of Cardiology Foundation. Published by Elsevier.
Objectives: The aim of this study was to examine the association among statins, dementia-free and disability-free survival, and cardiovascular disease (CVD) among healthy older adults using data from the ASPREE (Aspirin in Reducing Events in the Elderly) trial.
Methods: ASPREE was a randomized trial of 19,114 community-dwelling persons in Australia and the United States ≥65 years of age and free of documented CVD, dementia, and disability. Data were collected for those ≥70 years of age, and participants who took statins at baseline were compared with those who did not using Cox proportional hazards regression with inverse probability weighting. The primary outcome, referred to as "disability-free survival," was a composite of all-cause mortality, dementia, or persistent physical disability. Other outcomes included the individual components of the composite outcome, major adverse cardiovascular events, fatal CVD, myocardial infarction, and stroke.
Results: Of the 18,096 included participants (median age 74.2 years, 56.0% women), 5,629 took statins at baseline. Over a median follow-up period of 4.7 years, baseline statin use was not associated with disability-free survival or with the risk for all-cause mortality or dementia. However, it was associated with lower risks for physical disability and all cardiovascular outcomes.
Conclusions: Among healthy community-dwelling adults ≥70 years of age, statin use may be beneficial for preventing physical disability and CVD but not beneficial for prolonging disability-free survival or avoiding death or dementia. Future clinical trials are needed to confirm these findings.
|Item Type:||Refereed Article|
|Keywords:||aged, cardiovascular diseases, hydroxymethylglutaryl-CoA reductase inhibitors, primary prevention, survival|
|Research Division:||Biomedical and Clinical Sciences|
|Research Group:||Cardiovascular medicine and haematology|
|Research Field:||Cardiology (incl. cardiovascular diseases)|
|Objective Group:||Clinical health|
|Objective Field:||Clinical health not elsewhere classified|
|UTAS Author:||Zhou, Z (Dr Zhen Zhou)|
|UTAS Author:||Breslin, M (Dr Monique Breslin)|
|UTAS Author:||Nelson, MR (Professor Mark Nelson)|
|Web of Science® Times Cited:||14|
|Deposited By:||Menzies Institute for Medical Research|
Repository Staff Only: item control page